Adaptive Biotechnologies plans to separate its MRD diagnostics and Immune Medicine businesses by end of 2026.

Adaptive Biotechnologies announced it will separate its profitable Minimal Residual Disease (MRD) diagnostics business, which has grown significantly and reached profitability, from its Immune Medicine business, which focuses on AI-driven immune data discovery. The company believes separating these businesses will unlock their full potential, with MRD continuing under Adaptive and Immune Medicine exploring strategic alternatives outside the company. This move aims to enhance growth, value creation, and impact on patients, with a preferred separation path expected by the end of 2026.